Molecular Insight Pharmaceuticals, Inc. to Host Analyst Day Event and Webcast February 5, 2008
- Panel of Leading Clinicians to Discuss the Future of Molecular Medicine -
Cambridge, MA, January 22, 2008 – Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) today announced that it will host an Analyst Event on Tuesday, February 5, 2008 beginning at 8:30 a.m. Eastern Time in New York City. The program, “The Future of Radiopharmaceuticals: Improved Imaging and Treatment for Serious Diseases,” will feature a series of presentations and a panel discussion by leading clinicians on the topics of Molecular Medicine, Targeted Radiotherapeutics and Molecular Imaging Pharmaceuticals.
Investment professionals interested in attending Molecular Insight’s Analyst Event should contact Chris Erdman at (781) 235-3060 or molecularinsight@macbiocom.com.
| Presenters: |
R. Edward Coleman, M.D., Professor and Vice Chairman of the Department of Radiology and Director of the Department of Radiology and Nuclear Medicine at Duke University Medical Center
Vasken Dilsizian, M.D., Professor of Medicine and Diagnostic Radiology, Chief, Division of Nuclear Medicine and Director, Cardiovascular Nuclear Medicine and PET Imaging at the University of Maryland Medical Center
James E. Udelson, M.D., Associate Professor of Medicine and Associate Chief, Division of Cardiology and Director of Nuclear Cardiology at Tufts-New England Medical Center
Ronald L. Van Heertum, M.D., Professor and Vice Chairman of Radiology and Director of the Division of Nuclear Medicine, and Director of the Morton A. Kreitchman PET Center at Columbia University Medical Center
|
| Date: |
Tuesday, February 5, 2008 |
| Time: |
8:00 a.m. Registration and breakfast
8:30 a.m. Presentations commence
|
| Webcast: |
www.molecularinsight.com. Please click on the "Investor Relations" link on the homepage to access events at least five minutes prior to the start of the webcast. |
| Dial-In: |
800.299.7635 or 617.786.2901 (international) |
| Password: |
84547295 |
The presentation will be available via webcast and telephonic archive for 30 days beginning two hours after the completion of the live event.
About Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals (NASDAQ: MIPI) is a biopharmaceutical company specializing in the emerging field of molecular medicine, applying innovations in the identification and targeting of disease at the molecular level to improve healthcare for patients with life-threatening diseases. The company is focused on discovering, developing and commercializing innovative and molecular radiotherapeutics and molecular imaging pharmaceuticals with initial applications in the areas of oncology and cardiology. Its lead molecular radiotherapeutic product candidates, Azedra and Onalta, are being developed for detection and treatment of cancer. The company's lead molecular imaging pharmaceutical product candidate, Zemiva, is being developed for the diagnosis of cardiac ischemia, or insufficient blood flow to the heart. In addition, the company has a growing pipeline of product candidates resulting from application of its proprietary platform technologies to new and existing compounds. Molecular Insight Pharmaceuticals is based in Cambridge, Massachusetts and its website address is: www.molecularinsight.com.
Forward-Looking Statements
Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about AzedraTM, OnaltaTM, ZemivaTM and any other statements relating to product candidates, product development programs, the U.S. FDA, or the clinical trial process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Molecular Insight to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; expected contributions to the Company by Dr. Gottlieb; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Molecular Insight undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Contacts:
Corporate
Priscilla Harlan
Vice President, Corporate Communications
Molecular Insight Pharmaceuticals, Inc.
(617) 492-5554
Event Attendance
Chris Erdman
Vice President
MacDougall Biomedical Communications
(781) 235-3060
molecularinsight@macbiocom.com